Cardiol Therapeutics will engage in a casual discussion at Canaccord Genuity's 45th Annual Growth Discussion
Cardiol Therapeutics, a clinical-stage life sciences company, is making strides in the treatment of inflammatory heart diseases with its lead drug candidate, CardiolRx™. This oral solution of cannabidiol is currently in advanced clinical development for two conditions: recurrent pericarditis and acute myocarditis.
Progress in Acute Myocarditis Trials
The company's Phase II trial, ARCHER, in acute myocarditis recently announced promising topline results. CardiolRx™ demonstrated notable improvements in key cardiac magnetic resonance imaging endpoints after 12 weeks of treatment. These improvements included a reduction in extracellular volume (a marker of fibrosis and inflammation) and left ventricular mass. These findings support the potential therapeutic benefits of CardiolRx™ in acute myocarditis. The drug was also confirmed to be safe and well-tolerated in this population.
Ongoing Trials for Recurrent Pericarditis
In recurrent pericarditis, another inflammatory heart condition, CardiolRx™ has completed a Phase II pilot study (MAvERIC-Pilot) and is currently being evaluated in an ongoing Phase III MAVERIC trial. The company has also been granted Orphan Drug Designation by the US FDA for pericarditis, which includes recurrent pericarditis, facilitating its clinical development path.
Forward-Looking Statements
It's important to note that the forward-looking information contained in this press release reflects the current expectations or beliefs of Cardiol based on information currently available to it. Investors are cautioned not to rely on these forward-looking statements. The risks and uncertainties referred to in Cardiol's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, should be considered carefully.
Upcoming Presentation
Cardiol Therapeutics Inc. will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT. The replay of this event will be available for 90 days following the conference.
For More Information
For more details, contact Trevor Burns at +1-289-910-0855 or [email protected]. Cardiol's website is accessible at www.cardiolrx.com.
[1] ARCHER Phase II trial in acute myocarditis results [2] Cardiol Therapeutics Inc. receives Orphan Drug Designation for pericarditis [3] Cardiol Therapeutics Inc. to present ARCHER data at upcoming scientific meetings and submit for publication [4] Cardiol Therapeutics Inc. receives IND authorization from the US FDA for clinical studies evaluating CardiolRx™ in both recurrent pericarditis and acute myocarditis
This press release was provided by Newsfile via QuoteMedia. The press release source can be found at https://www.newsfilecorp.com/release/261960.
- In the realm of health-and-wellness and life science, Cardiol Therapeutics, a clinical-stage company, is exploring the finance and investing potential of its lead drug candidate, CardiolRx™, in the treatment of heart diseases, specifically inflammatory conditions like acute myocarditis and recurrent pericarditis.
- Notably, Cardiol's Phase II trial, ARCHER, focused on acute myocarditis, has recently announced promising results, showing that CardiolRx™ improved key cardiac magnetic resonance imaging endpoints and reduced extracellular volume, supporting its therapeutic benefits.
- For the business aspect, CardiolRx™ is currently undergoing further trials for recurrent pericarditis and has been granted Orphan Drug Designation by the US FDA, which will facilitate its clinical development path and possibly attract potential investors.
